

1 **Short-Form Paper:**

2

3 **Comparative accuracy of the InBios Scrub Typhus Detect™ IgM Rapid Test for the detection of**
4 **IgM antibodies using conventional serology.**

5

6 Hugh W.F. Kingston^{1,2}, Stuart D. Blacksell^{1,3}, Ampai Tanganuchitcharnchai¹, Achara

7 Laongnualpanich⁴, Buddha Basnyat⁵, Nicholas P.J. Day^{1,3}, and Daniel H. Paris^{1,3,*}

8

9 ¹ Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University,
10 420/6 Rajvithee Road, 10400 Bangkok, Thailand.

11 ² Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia

12 ³ Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, Churchill
13 Hospital, Old Road, Headington, Oxford, OX3 7LJ, United Kingdom.

14 ⁴ Chiangrai Prachanukhru Hospital, Chiangrai, Thailand

15 ⁵ Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Kathmandu, Nepal

16

17 ***Corresponding author**

18 Assoc. Professor Daniel H. Paris, MD PhD

19 Mahidol-Oxford Tropical Medicine Research Unit (MORU),

20 3rd Floor, 60th Anniversary Chalermprakiat Building, Faculty of Tropical Medicine, Mahidol University,
21 420/6 Rajvithee Rd, Bangkok 10400, Thailand

22 Tel + (0) 66 2 203 6373 Fax + (0) 66 2 354 9169

23 Email: pariqi@tropmedres.ac

24 **Abstract**

25 This study investigated the comparative accuracy of a recombinant p56 kDa type-specific antigen-
26 based rapid diagnostic test (RDT) for scrub typhus for the detection of IgM antibodies using
27 conventional serology, in well-characterized serum samples from undifferentiated febrile illness
28 patients. The RDT showed high specificity and promising comparative accuracy with 82% sensitivity
29 and 98% specificity for samples defined positive at the IgM IFA positivity cutoff titer of $\geq 1:1,600$,
30 versus 92% and 95% at $\geq 1:6,400$, respectively.

31 **Short report (<1,500 words)**

32 There is an urgent need for inexpensive accurate point-of-care rapid diagnostic tests (RDT) for scrub
33 typhus. Clinical diagnosis on admission is rendered difficult due to the non-specificity of presenting
34 symptoms, like fever and skin rash. The presence of an eschar at the mite inoculation site is a
35 valuable diagnostic clue when found in combination with a positive RDT result, with a positive
36 predictive value (PPV) and negative predictive value (NPV) of 84.9% and 93.0% respectively, but
37 unfortunately the varying occurrence of this lesion, especially in endemic settings limits this approach
38 (1). Currently, three modalities are used for the diagnosis of scrub typhus; culture, nucleic acid and
39 antibody detection. Culture from patient samples is insensitive, laborious and expensive; nucleic acid
40 detection is accurate in the early phase of infection, but sensitivity falls with fever duration beyond 9
41 days (2). Antibody detection, traditionally by indirect immunofluorescence (IFA), requires skilled
42 technicians and expensive equipment, and is limited by the problem of background titers in endemic
43 settings, antigen selection and standardization (3). The rigorous use of paired serum samples with a
44 four-fold or greater antibody titer rise required as diagnostic endpoint, has overcome some issues, but
45 confounding factors include pre-existing antibodies and cross-reactivity. Attempts at improving the
46 gold standard have included combining all modalities into the scrub typhus infection criteria (STIC)
47 proposed for diagnostic assay validations (2). However, the single admission endpoint titer conundrum
48 is not yet adequately resolved. Recent Bayesian Latent Class Modeling (LCM) data have highlighted
49 the low specificity of admission and paired dynamic IFA IgM titers with low convalescent titers, such as
50 a ≥ 4 -fold rise to $\leq 1:800$ (1), (*pers comm* Cherry Lim).

51 An affordable, accurate point-of-care RDT that demonstrates a positivity cut-off at the population
52 background antibody titer could potentially replace the admission IFA and impact patient management
53 positively by guiding administration of specific treatment. More data on the variation of endemic
54 background cut-off titers between geographical regions is required, and more sensitive RDTs (i.e.
55 RDTs that provide a positive result at a lower antibody titer) might be better in non-endemic regions
56 and less sensitive RDTs that are positive at higher cutoff titers are more useful in endemic regions. A

57 comparative analysis of an RDT in an endemic region for scrub typhus has shown improved specificity
58 using IgM over total antibody, while maintaining sensitivity (4). IgM is produced immediately after
59 pathogen exposure, with a shorter half-life in blood and lymphatics than the more pathogen-specific
60 IgG, which is produced later and provides a long-lasting response dependent on the pre-existing
61 exposure of the individual (5). Although IgG can persist for a long time and is thought to be more
62 specific in paired samples, it can be associated with higher RDT false positivity rates in endemic areas
63 where the population is continuously exposed. Two important questions remain unresolved; what is
64 the longevity of IgM and IgG in human scrub typhus, and which isotype appears earlier in naïve and
65 exposed populations? Non-human primate timecourse studies have shown that IgM and IgG can
66 appear almost simultaneously in cynomolgus macaques (6, 7).

67

68 In this study we evaluated a new commercial immunochromatographic-based RDT based on *O.*
69 *tsutsugamushi* recombinant p56kD type-specific antigen (TSA) of Karp, Kato, Gilliam and TA716
70 strains (Scrub Typhus Detect IgM Rapid Test, InBios International Inc., Seattle WA, USA). Two RDT
71 prototype versions with different antibody IgM detection modalities were tested using either polyclonal
72 (pAb) or monoclonal (mAb) secondary antibodies.

73 The InBios RDT tests were performed from the same batch and lot (Part #800231 and Lot #NB273/52
74 respectively) using serum samples (10 uL serum per test strip) according to the manufacturer's
75 instructions. Previously characterized admission serum samples (total n=100) were used, collected
76 from febrile illness patients enrolled into ethically and Institutional Review Board (IRB) fully approved
77 prospective 'causes-of-fever' studies performed in Udon Thani, NE Thailand (2000 to 2001; n=85) and
78 Kathmandu, Nepal (2008 to 2011; n=15) (8, 9). The included samples consisted of confirmed scrub
79 typhus cases (n=21) meeting any of the previously defined stringent scrub typhus infection criteria
80 (STIC); culture-positivity and/or admission IgM antibody titer of >1:12,800 and/or a ≥4-fold rising IgM
81 IFA antibody titer and/or positivity for ≥2 out of 3 PCR gene targets. Murine typhus cases with paired
82 dynamic serology and/or qPCR positivity (n=23) and dengue cases with NS1 antigen positivity (n=5)

83 were included. The other cases represented patients with undifferentiated febrile illness (n=51) with
84 negative test results for scrub typhus, murine typhus and NS1 antigen tests (2, 10).

85 The IFA used pooled *O. tsutsugamushi* Karp, Kato, Gilliam antigens to detect IgM antibodies with IFA
86 slides produced by the Australian Rickettsial Reference Laboratory (Geelong, Australia). Patient sera
87 were serially 2-fold diluted from 1:100 to 1:25,600 and the endpoint was determined by two
88 experienced staff members as the highest titer displaying specific fluorescence (11). Three
89 independent laboratory technicians read the developed RDTs blinded to each other's results and the
90 majority interpretation was final. Sensitivity and specificity were calculated using a range of IFA
91 endpoint cutoff titers for positivity and binomial 95% confidence intervals (95% CI) were calculated.
92 Kappa statistics were calculated for inter-reader variation. Statistical analysis and logistic regression
93 (Figure 1) were performed using Stata/IC software (Version 13.0, Statacorp, College Station, TX,
94 USA) and plotted using R version 3.1.1 (available on www.r-project.org).

95

96 The challenges of a point-of-care RDT are comparable to that of a single titer admission IFA, albeit
97 with a simplified procedure and clear-cut endpoint. In this study, we did not attempt to estimate the
98 classic diagnostic accuracy of the InBios RDT— this would require a prospective study design – but
99 rather attempted to define the antibody titer associated with optimal RDT performance in a set of
100 characterized samples, as its comparative accuracy. Hence, we assessed the agreement of RDT
101 positivity rates against a range of samples with pre-defined different IgM IFA admission titers. Table 1
102 summarizes the assay results and the respective sensitivity and specificity values at the different IFA
103 cutoff titers.

104 The proportion of RDTs with a positive result at each IFA IgM titer increased with higher IFA IgM titers
105 (test for trend; $p < 0.001$). All of the RDTs (100%) provided negative results at IFA titers of $\leq 1:400$ and
106 all of the RDTs (100%) provided positive results at titers of $\geq 1:25,600$. The results show that both
107 versions of the new test identifies the same number of positive samples identified by IFA when the
108 reciprocal antibody cut-off titer is high, thereby giving 100% sensitivity. Although the tests agree well if

109 the sample has high antibody levels, the new test misses some of the IFA-positive samples at low cut-
110 off titers with subsequent reduction of sensitivity. Plotting the proportion of positive RDTs per different
111 IFA titers delineates a sigmoidal relationship, with increasing proportions of RDT positivity at titers
112 $\geq 1:3,200$ (Figure 1). This response was comparable with the previously assessed PanBio RDT (12).
113 There was minimal difference between the two secondary antibody versions in terms of proportion
114 positive at the different IFA titers. The interpretation of bands was perceived more difficult due to
115 weaker, paler and more smeared bands in positive samples using RDTs based on mAbs compared to
116 RDTs based on pAbs, which was reflected by a marginally higher kappa, 0.97 vs 0.93 for the high and
117 low antigen density versions respectively (data not shown).
118 The RDTs assessed in this study were specific and sensitive for the detection of high IFA titer samples
119 only. This RDT would therefore be expected to perform well in endemic areas where a higher
120 background antibody titer would be expected in the population, as low titers would result in a negative
121 RDT result and higher titers detected with good diagnostic accuracy.
122 It is noteworthy that a >64-fold difference in IgM antibody concentration exists between the samples
123 with titers of 1:400 and >1:25,600. In samples with a low IFA titer ($\leq 1:400$) the RDT results were
124 generally negative, contributing to a high specificity. Currently, it is not known if the antibodies in
125 serum samples with an IFA titer of 1:400 may be different from the antibodies in samples with a
126 1:25,600 titer, either in affinity or target. However we have shown in recent Bayesian LCM analyses,
127 that paired dynamic IFA IgM titers with low convalescent titers, such as a ≥ 4 -fold rise to $\leq 1:800$
128 contribute to low specificity of the IFA assay, and as such a higher endpoint cut-off positivity titer
129 needs to be considered (1), (Lim C, *pers comm*).
130 The choice of an IFA positivity cut-off endpoint titer at 1:400 over 1:1,600 to 1:6,400 results in a
131 stepwise improvement of the InBios RDT diagnostic accuracy, with sensitivities (95% CI) from 52%
132 (32-71), over 82% (57-96) to 92% (64-100) while retaining a specificity of $\geq 94\%$ (Table 1). The size of
133 the study dataset did not allow for in-depth and detailed analyses, however it can be safely assumed
134 that the positivity cut-off titer of the InBios RDT lies around the 1:1,600 – 1:3,200 titer range.

135 The RDT under evaluation, may have benefited from the inclusion of antigenically disparate
136 recombinant immunodominant p56kDa antigens from four *O. tsutsugamushi* strains, three more than
137 the PanBio IgM RDT and one more than the reference IFA; the additional *O. tsutsugamushi* TA716
138 strain. A study limitation is that the benefit of a broader antigen spectrum covered by the RDT would
139 have gone unnoticed in the current evaluation as anti-TA716 antibodies would not have been detected
140 by the IFA used (based on Karp, Gilliam and Kato strains), which would have increased the RDT false
141 positive rate, due to false negative IFA results.

142 In conclusion, the InBios RDTs tested here show promising performance characteristics for use in
143 endemic zones where the admission IgM IFA positivity cutoff titer would lie around a titer of 1:1,600 –
144 1:3,200. The RDT assay based on polyclonal endpoint detection is preferable for a prospective
145 evaluation. Attention should be given to understanding why the RDTs are negative at $\leq 1:400$ and how
146 this can be improved to develop tests for non-endemic zones.

147

148

149 **Acknowledgements**

150 We are grateful for the assistance of the clinical teams during the collection of sample specimens for
151 this study. This work was supported by the Wellcome Trust of the United Kingdom. The RDTs
152 assessed in this study were provided by InBios International Inc.

Table 1. Summary of characterized patient admission serum samples and rapid diagnostic test (RDT) performance in this study. The results are stratified by their IFA IgM antibody positivity titers (horizontal rows) with corresponding InBios RDT diagnostic accuracies reported separately for IgM detection modalities, polyclonal (pAb) versus monoclonal antibodies (mAb). Although the number of characterized samples with confirmed scrub typhus was 21/100, more samples had low IFA IgM positivity, i.e. of all samples, if IFA cutoff titer was chosen at $\geq 1:400$, then 14 of these were true positives (TP) and 13 were false negatives (FN) - with rising IFA IgM titers, the rate of FN decreased.

IFA reciprocal cutoff titer	Samples with IFA IgM titer cutoff (N/100)	RDT Version*	RDT results				Sensitivity % (95% CI)	Specificity % (95% CI)
			TP (N)	FP (N)	FN (N)	TN (N)		
≥ 400	27	pAb	14	2	13	71	52 (32-71)	97 (90-100)
		mAb	14	3	13	70	52 (32-71)	96 (88-99)
$\geq 1,600$	17	pAb	14	2	3	81	82 (57-96)	98 (92-100)
		mAb	14	3	3	80	82 (57-96)	96 (90-99)
$\geq 6,400$	13	pAb	12	4	1	83	92 (64-100)	95 (89-99)
		mAb	12	5	1	82	92 (64-100)	94 (87-98)
$\geq 25,600$	11	pAb	11	5	0	84	100 (72-100)	94 (87-98)
		mAb	11	6	0	83	100 (72-100)	93 (86-97)

Footnote: *RDT version; pAb=polyclonal secondary antibodies; mAb=monoclonal secondary antibodies. N = number. TP=True positive RDT; FP = false positive RDT; FN=False negative RDT; TN=true negative RDT. CI = confidence interval.

Figure 1. Relationship between IFA titer and rapid diagnostic test (RDT) positivity

This figure shows the proportion of positive RDTs at different IFA titers plotted on a logarithmic scale. Logistic regression was used to describe the sigmoidal relationship between RDT positivity and IFA titer, illustrating the low proportions of RDT positivity below IFA titers of 1:3,200. No significant difference between the two RDT versions was observed (secondary polyclonal antibody detection in red and monoclonal in blue).

References

1. **Lim C, Paris DH, Blacksell SD, Laongnualpanich A, Kantipong P, Chierakul W, Wuthiekanun V, Day NPJ, Cooper BS, Limmathurotsakul D.** 2015. How to determine the accuracy of an alternative diagnostic test when it is actually better than the reference tests: A re-evaluation of diagnostic tests for scrub typhus using Bayesian LCMs. *PLoS One* **10**:e0114930.
2. **Paris DH, Blacksell SD, Nawtaisong P, Jenjaroen K, Teeraratkul A, Chierakul W, Wuthiekanun V, Kantipong P, Day NPJ.** 2011. Diagnostic accuracy of a loop-mediated isothermal PCR assay for detection of *Orientia tsutsugamushi* during acute scrub typhus infection. *PLoS Negl Trop Dis* **5**:e1307.
3. **Blacksell SD, Bryant NJ, Paris DH, Doust JA, Sakoda Y, Day NPJ.** 2007. Scrub typhus serologic testing with the indirect immunofluorescence method as a diagnostic gold standard: a lack of consensus leads to a lot of confusion. *Clin Infect Dis* **44**:391-401.
4. **Blacksell SD, Jenjaroen K, Phetsouvanh R, Wuthiekanun V, Day NPJ, Newton PN, Ching W-M.** 2010. Accuracy of AccessBio Immunoglobulin M and total antibody rapid immunochromatographic assays for the diagnosis of acute scrub typhus infection. *Clin Vaccine Immunol* **17**:263-266.
5. **Bourgeois AL, Olson JG, Fang RC, Huang J, Wang CL, Chow L, Bechthold D, Dennis DT, Coolbaugh JC, Weiss E.** 1982. Humoral and cellular responses in scrub typhus patients reflecting primary infection and reinfection with *Rickettsia tsutsugamushi*. *Am J Trop Med Hyg* **31**:532-540.
6. **Chattopadhyay S, Jiang J, Chan T-C, Manetz TS, Chao C-C, Ching W-M, Richards AL.** 2005. Scrub typhus vaccine candidate Kp r56 induces humoral and cellular immune responses in cynomolgus monkeys. *Infect Immun* **73**:5039-5047.
7. **Paris DH, Chattopadhyay S, Jiang J, Nawtaisong P, Lee JS, Tan E, Dela Cruz E, Burgos J, Abalos R, Blacksell SD, Lombardini E, Turner GD, Day NPJ, Richards AL.** 2015. A nonhuman primate scrub typhus model: Protective immune responses induced by pKarp47 DNA vaccination in cynomolgus macaques. *J Immunol* **194**:1702-1716.
8. **Sonthayanon P, Chierakul W, Wuthiekanun V, Phimda K, Pukrittayakamee S, Day NP, Peacock SJ.** 2009. Association of high *Orientia tsutsugamushi* DNA loads with disease of greater severity in adults with scrub typhus. *J Clin Microbiol* **47**:430-434.

9. Thompson CN, Blacksell SD, Paris DH, Arjyal A, Karkey A, Dongol S, Giri A, Dolecek C, Day N, Baker S, Thwaites G, Farrar J, Basnyat B. 2015. Undifferentiated febrile illness in Kathmandu, Nepal. *Am J Trop Med Hyg* **92**:875-878.
10. Blacksell SD, Jarman RG, Bailey MS, Tanganuchitcharnchai A, Jenjaroen K, Gibbons RV, Paris DH, Premaratna R, de Silva HJ, Laloo DG, Day NPJ. 2011. Evaluation of six commercial point-of-care tests for diagnosis of acute dengue infections: the need for combining NS1 antigen and IgM/IgG antibody detection to achieve acceptable levels of accuracy. *Clin Vaccine Immunol* **18**:2095-2101.
11. Luksameetanasan R, Blacksell SD, Kalambaheti T, Wuthiekanun V, Chierakul W, Chueasuwanchai S, Apiwattanaporn A, Stenos J, Graves S, Peacock SJ, Day NPJ. 2007. Patient and sample-related factors that effect the success of in vitro isolation of *Orientia tsutsugamushi*. *Southeast Asian J Trop Med Public Health* **38**:91-96.
12. Blacksell SD, Paris DH, Chierakul W, Wuthiekanun V, Teeratakul A, Kantipong P, Day NPJ. 2012. Prospective evaluation of commercial antibody-based rapid tests in combination with a loop-mediated isothermal amplification PCR assay for detection of *Orientia tsutsugamushi* during the acute phase of scrub typhus infection. *Clin Vaccine Immunol* **19**:391-395.

